Sorafenib Treatment in 13 Patients with Acute Myeloid Leukemia and Activating FLT3 Mutations in Combination with Chemotherapy or as Monotherapy

Publisher： Karger

E-ISSN： 1421-9662|124|3|153-159

ISSN： 0001-5792

Source： Acta Haematologica, Vol.124, Iss.3, 2010-10, pp. : 153-159

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Treatment with FLT3 inhibitor in patients with FLT3‐mutated acute myeloid leukemia is associated with development of secondary FLT3–tyrosine kinase domain mutations

By  

CANCER, Vol. 120, Iss. 14, 2014-07 ,pp. : 2142-2149

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 5, 2015-06 ,pp. : 694-700

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 6, 2015-06 ,pp. : 1048-1054

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Implications of Non-A-Type NPM1 and FLT3 Mutations in Patients with Normal Karyotype Acute Myeloid Leukemia

By  

Acta Haematologica, Vol. 127, Iss. 2, 2011-11 ,pp. : 63-71

Karger

Access to resources Recommend Favorite

Implications of FLT3 Mutations in the Therapy of Acute Myeloid Leukemia

By  

Reviews on Recent Clinical Trials, Vol. 2, Iss. 2, 2007-05 ,pp. : 135-141

Bentham Science Publishers

Access to resources Recommend Favorite